---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-283667"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:54:58.654879+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cullinan Oncology reports Q3 net loss $24.9M; initiates pivotal zipalertinib study

## Summary
- Initiated pivotal study for zipalertinib in EGFR exon 20 NSCLC; cohort to evaluate 150 mg BID with food.
- Increased ownership in MICA (CLN-619) from 54% to 92% for $30.7M cash.
- Cash and investments $606.7M at Sept 30, 2022; runway extends beyond key milestones.
- Net loss before noncontrolling interest $24.9M; R&D expenses $19.7M, G&A $10.1M.
- Appointed Jacquelyn Sumer as CLO and Dr. David Ryan to Board; IND filings for CLN-617, CLN-978 on track for H1 2023.

## SEC filing metadata
- accession: 0001193125-22-283667
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/0001193125-22-283667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/d371812d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-283667
- JSON: https://secwatch.observer/filing/0001193125-22-283667.json
- Plain text: https://secwatch.observer/filing/0001193125-22-283667.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000119312522283667/0001193125-22-283667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.